About | Free Trial

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Cooper Collins?

Mr. Cooper Collins C.

Chairman and Chief Executive Officer

Fortis BioPharma

Email: c***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

Fortis BioPharma is a healthcare company primarily focused on developing and marketing ground breaking therapies that this generation of patients and consumers demand. The primary goal for Fortis is to develop natural options for patients first, when nece ... more

Find other employees at this company (1)

Background Information

Employment History

Particle Sciences , Inc.


TherapeuticsMD, Inc.

President and Chief Executive Officer


Biotech Hedge Fund Manager

SigmaBleyzer LLC


Advisory Board Member



Nicholls State University


Nicholls State University

Web References (182 Total References)

Cooper C. ...

www.sec.gov [cached]

Cooper C. Collins

Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma since June 2015. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
Thompson, Carroll, Collins, LaPenta, Jr., Russell and Segal, is an independent director, as “independence” is defined under the applicable rules and regulations of the SEC and the listing standards of the NYSE MKT, because they do not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.
LaPenta, Jr., Segal, Collins, and Russell, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
Collins, Thompson, and Carroll served as members of the Compensation Committee.
Collins, Thompson, or Carroll have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Exchange Act.

"When Fortis BioPharma decided ...

fortisbiopharma.com [cached]

"When Fortis BioPharma decided to create Naturmetic we did so with the consumer in mind, we imagined someone leading a healthy, fast paced lifestyle and naturally Korie fit the brand," said Cooper Collins, CEO of Fortis BioPharma.

VelocityHealth Securities

www.velocityhealth.com [cached]

Cooper C. Collins, Former CEO Pernix Therapeutic Holdings, Inc.

Cooper C. Collins is the Former CEO of Pernix Therapeutic Holdings, Inc. a specialty pharmaceutical company focused on the pediatric sector. During his six year career with Pernix, Mr. Collins has worked in every capacity from sales representative to the executive level. Mr. Collins has been responsible for acquiring products and assets, attracting investors and increasing the overall efficiency of the organization. As a sales representative, he improved territory sales by over 300% in the first year and quickly moved into management. While serving as President, Mr. Collins has contributed to the Company's overall profit increasing over 100% from the year ended December 31, 2007 to the year ended December 31, 2008. Prior to joining Pernix, Mr. Collins was employed by the NFL franchise The New Orleans Saints in their media relations department for three years. He also developed and sold a small internet company while earning a B.A. and a M.B.A. on a football scholarship from Nicholls State University.


www.sec.gov [cached]

0001485508 Collins Cooper C. 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR BOCA RATON, FL 33487 1 0 0 0


www.sec.gov [cached]

0001485508 Collins Cooper C. 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR BOCA RATON, FL 33487 1 0 0 0

Similar Profiles

Other People with this Name

Other people with the name Collins

Randy Collins
The GSSM Foundation

Monti Collins
Re/max Allegiance

Beverly Collins
Re/max Allegiance

Lauren Collins
Glenwood School Inc

Thomas Collins
Washington State University

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory